COST-MINIMIZATION OF VILANTEROL / UMECLIDINIUM VERSUS OLODATEROL / TIOTROPIUM IN THE BASIC THERAPY OF SEVERE AND VERY SEVERE COPD
The recently introduced novel drug combinations for the treatment of COPD are based on long-acting beta-agonists (vilantererol / umeclidinum bromide) and long-acting anticholinergics (olodaterol / tiotropium bromide). In addition to their beneficial clinical effects, these medications have an impact...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2017-08-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/196 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|